Medical products maker Convatec rises after robust 2026 outlook on growing demand
Nov 13 (Reuters) - Britain's Convatec CTEC.L on Thursday forecast double-digit percentage growth in 2026 profit, boosting its shares as much as 8%, as the company banks on launches of products such as wound dressings and rising demand to bolster sales in key markets.
Healthcare firms are preparing for U.S. tariffs and pricing pressures alongside national security probes into imports of medical equipment, but Convatec has been streamlining operations to boost margins and ramping up investments to cater to demand.
The company, which also makes catheters and drug delivery systems, forecast adjusted earnings per share to grow at a double-digit rate next year after it said it would deliver on its targets for the current year. It tightened its 2025 organic revenue growth forecast to 6% to 6.5% excluding skin graft InnovaMatrix, from 5.5% to 7% previously.
"We're making good progress with our new product launches," CEO Jonny Mason said on an investor call.
"It's taken a while, but sales are building very nicely now in the U.S., and we expect that success to follow in Europe as well," he added.
COMPANY CAUTIOUS ABOUT U.S. LOWERING REIMBURSEMENT COSTS
North America and Europe are the company's two biggest markets, with more than half of its sales from North America.
Convatec expects 5% to 7% growth in organic sales in 2026, but that forecast excludes InnovaMatrix, as the company exercises caution around a U.S. decision this year to lower reimbursement prices in government programs to cut costs.
The company said it faces challenges if the policy changes are implemented in their current form, but Mason told Reuters the U.S. would "remain a very strong and important market" for Convatec despite the pressures.
"Supportive colour around FY26 should provide some relief that underlying performance remains intact," J.P. Morgan analysts said in a note.
Convatec shares were up 5.8% at 1453 GMT and were among the top gainers on the blue-chip FTSE 100 .FTSE index, which was down 0.8%.
Related Articles
Netflix Stock Analysis: Why Netflix Stock Keeps Falling, and When Should Investors Buy Netflix Stock?
While the final terms for Netflix's acquisition of WBD remain uncertain in the short term, we view the recent decline, driven by market sentiment, as a significant long-term undervalued opportunity. The return to more realistic valuations enhances the investment appeal of Netflix stock.
Musk Confirms SpaceX 2026 IPO: The Dual ‘Trillion-Dollar’ Bet with Hidden Risks
TradingKey - Elon Musk has confirmed speculation that his space exploration company, SpaceX, is preparing for an IPO as early as 2026. The potential listing, which could value SpaceX at over $1 trillion, might catapult it into the ranks of the world's top ten most valuable companies. This raises a
Judgment on the Fed's December Rate Cut and 2026 Monetary Policy Trend: Identifying Opportunities in the U.S. Stock Market
TradingKey - The Federal Reserve is likely to halt its rate-cutting cycle before the end of Q2 2026...The magnitude of rate cuts in Q3 and Q4 2026 is expected to far exceed current market expectations...U.S. equities are highly likely to follow a "bearish-then-bullish" trajectory throughout 2026.
Why Is the "Altcoin Season" Delayed? Will Altcoins Perish?
The anticipated "altcoin season" has yet to materialize, constrained by a lack of fresh market capital and Bitcoin's continued dominance in absorbing available funds. This does not mean all altcoins will perish; however, a segment of these tokens will gradually exit the market. Therefore, caution is
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?
